Astrazeneca and Vertex Join the Catalis Network
CATALIS Quebec is very proud to announce that pharmaceutical companies AstraZeneca and Vertex are joining the CATALIS Network. As new members, they join Abbvie, Bayer, Boehriger Ingelheim, GSK, Merck, Novartis, Pfizer, Roche, Sanofi and Takeda. Together, the partners support CATALIS in its mission to optimize the clinical research environment to accelerate the development of innovative patient care and maximize private investment in the province.
“We’re excited to be partnering with CATALIS and believe their FAST TRACK Evaluation Service is a significant step in helping to optimize and accelerate the launch timeline of clinical trials in Quebec – strengthening the province’s position and reputation as a world-class hub in medical research. By simplifying the regulatory environment and accelerating clinical launch timelines we’re able to better attract new clinical studies to Quebec in such areas as breast and lung cancer, severe asthma, cardiovascular diseases and more – helping Canadian patients to gain early access to and potentially benefit from new medical innovations.” – Kiersten Combs – President, AstraZeneca Canada
“Quebec’s leadership in clinical research and in rare diseases makes it a unique place in Canada. As Vertex continues to advance its clinical and research programs, we are confident that our partnership with CATALIS will help to provide to Quebec patients a quick access to potentially innovative treatments.” – Michael Siauw, General Manager, Vertex Pharmaceuticals (Canada) Incorporated